相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
H. Eidtmann et al.
ANNALS OF ONCOLOGY (2010)
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
R. E. Coleman et al.
BRITISH JOURNAL OF CANCER (2010)
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells
Tilman D. Rachner et al.
CANCER LETTERS (2010)
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
Mohamed S. Zaghloul et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Fluorescent Risedronate Analogues Reveal Bisphosphonate Uptake by Bone Marrow Monocytes and Localization Around Osteocytes In Vivo
Anke J. Roelofs et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women?
Michael Gnant
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
Rebecca Aft et al.
LANCET ONCOLOGY (2010)
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
E. Terpos et al.
LEUKEMIA (2010)
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer
Kishan J. Pandya et al.
LUNG CANCER (2010)
The Molecular Basis of Bisphosphonate Activity: A Preclinical Perspective
Jonathan Green et al.
SEMINARS IN ONCOLOGY (2010)
Potential Anticancer Properties of Bisphosphonates
Helen L. Neville-Webbe et al.
SEMINARS IN ONCOLOGY (2010)
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting
Mateya Trinkaus et al.
SUPPORTIVE CARE IN CANCER (2010)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E. Terpos et al.
ANNALS OF ONCOLOGY (2009)
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro
Johanna Raikkonen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients
Daniele Santini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
Adam M. Brufsky et al.
CLINICAL BREAST CANCER (2009)
Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung Cancer
Vera Hirsh
CLINICAL LUNG CANCER (2009)
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
Peyman Hadji
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
Kostantinos Zarogoulidis et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Anti-Angiogenic Property of Zoledronic Acid by Inhibition of Endothelial Progenitor Cell Differentiation
Jun Yamada et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
David P. Dearnaley et al.
LANCET ONCOLOGY (2009)
Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis
Manav Korpal et al.
NATURE MEDICINE (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells
Fraser P. Coxon et al.
BONE (2008)
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
Allan Lipton et al.
CANCER (2008)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto et al.
CANCER (2008)
New research findings on zoledronic acid: Survival, pain, and anti-tumour effects
Fred Saad
CANCER TREATMENT REVIEWS (2008)
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
Vera Hirsh et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites
Y. Shiozawa et al.
LEUKEMIA (2008)
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M. Aapro et al.
ANNALS OF ONCOLOGY (2008)
Zoledronic acid and survival in breast cancer patients with bone Metastases and elevated markers of osteoclast activity
Allan Lipton et al.
ONCOLOGIST (2007)
Meta-analysis of clodronate and breast cancer survival
T. C. Ha et al.
BRITISH JOURNAL OF CANCER (2007)
Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
Agustin Aviles et al.
MEDICAL ONCOLOGY (2007)
Treatment-related osteoporosis in men with prostate cancer
Matthew R. Smith
CLINICAL CANCER RESEARCH (2006)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis
K Thompson et al.
MOLECULAR PHARMACOLOGY (2006)
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia et al.
ENDOCRINE-RELATED CANCER (2006)
A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates
H Mönkkönen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
T Powles et al.
BREAST CANCER RESEARCH (2006)
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
F Saad et al.
BJU INTERNATIONAL (2005)
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial
N Kohno et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone Metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline
K Mystakidou et al.
MEDICAL ONCOLOGY (2005)
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients
G Ferretti et al.
ONCOLOGY (2005)
Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis
DJ Hosfield et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation
JP Coxon et al.
BJU INTERNATIONAL (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)
BQ Pan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
I Fogelman et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Fever after zoledronic acid administration is due to increase in TNF-α and IL-6
G Dicuonzo et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2003)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma
A Lipton et al.
CANCER (2003)
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group
LS Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
HD Menssen et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts
V Viereck et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer
CL Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
EV McCloskey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
分享论文
